Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
| Inventor | Institute |
|---|---|
| Julian Gannon | Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| SKU: | 151244 |
|---|---|
| Product description: | Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase. |
| Alternate name: | Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase; CDKN2; CDC2-Related Protein Kinase; P33(CDK2) |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Immunogen: | Human recombinant Cdk2 |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 151244 |
|---|---|
| Provenance and Ownership: | The Anti-Cdk2 [AN4.3] is owned by Cancer Research UK. CancerTools supplies the Anti-Cdk2 [AN4.3] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Cdk2 [AN4.3] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Genetics |
| Application: | ELISA ; FACS ; IP ; WB |
| Target: | Cyclin-dependent kinase 2 (cdk2) |
| Reactivity: | Human ; Mouse ; Xenopus laevis |
| Clone: | AN4.3 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Syafrizayanti et al. 2017. Sci Rep. 7:39756. PMID: 28045055. Personalised proteome analysis by means of protein microarrays made from individual patient samples. Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan. Chu et al. 2016. Journal of Fn Foods. 23:614-627 Xu et al. 2010. Biol Pharm Bull. 33(5):743-51. PMID: 20460749. Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting. Ottewell et al. 2009. Mol Cancer Ther. 8(10):2821-32. PMID: 19789217. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-Integrins aL, aX, aMb2 [24] |
Key Info
Anti-Integrins aL, aX, aMb2 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.